ExoXpert partners with Neucore Bio for advanced exosome loading 


ExoXpert has partnered with Neucore Bio to leverage ExoXpert’s platform for evaluation of advanced exosome loading. 

Under the agreement, ExoXpert will test and optimise efficient loading of proprietary payloads into exosomes as part of Neucore’s Fibroblast EV Engineering (FiXE(R)) discovery platform.  

“This collaboration is an important step in the loading validation and application of our FiXE platform using advanced, non-viral exosomes for therapeutic delivery,” said Dr Kenneth Morand, CEO, Neucore Bio. “We believe ExoXpert’s demonstrated exosome experience with its ExoPulse platform will enable a highly efficient and collaborative process to answer this critical question in our scientific strategy.”  

Hugues Wallemacq, CEO,  ExoXpert and EXO Biologics, said: “ExoXpert has started working with a significant number of international cell and gene therapy developers that need a combination of exosome manufacturing and knowledge to develop new products for the benefit of patients. Partnering with Neucore will enable ExoXpert to further extend ExoXpert’s expertise in loading exosomes to Neucore’s FiXE platform.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free